{"nctId":"NCT00907426","briefTitle":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","startDateStruct":{"date":"2009-08"},"conditions":["Hypotrichosis"],"count":368,"armGroups":[{"label":"Bimatoprost 0.03% Followed by Bimatoprost 0.03%","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost 0.03% solution"]},{"label":"Bimatoprost 0.03% Followed by Vehicle","type":"OTHER","interventionNames":["Drug: Bimatoprost 0.03% solution","Drug: Vehicle solution"]},{"label":"Vehicle Followed by Bimatoprost 0.03%","type":"OTHER","interventionNames":["Drug: Bimatoprost 0.03% solution","Drug: Vehicle solution"]}],"interventions":[{"name":"Bimatoprost 0.03% solution","otherNames":["LATISSE™"]},{"name":"Vehicle solution","otherNames":["LATISSE™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who have inadequate eyelashes due to natural causes and are not satisfied with their eyelash appearance.\n* For the post-chemotherapy population: subjects who have inadequate eyelashes following a complete course of chemotherapy treatment and are not satisfied with their eyelash appearance, are considered free of cancer and are well enough to complete the study.\n\nExclusion Criteria:\n\n* Subjects with unequal right and left eyelashes, any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants, eyelash extension application.\n* Any use of over the counter or prescription use eyelash growth products.\n* Subjects requiring eye drop medications for glaucoma.\n* Females who are pregnant, nursing or planning a pregnancy during the study or who are of childbearing potential and not using a reliable method of contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treatment Responders at Month 4","description":"Percentage of Treatment Responders at Month 4 defined by: a) at least a 1-grade improvement from baseline in the Global Eyelash Assessment (GEA) score, AND b) at least a 3-point improvement from baseline in the total score for Domain 2 of the Eyelash Symptom Questionnaire (ESQ). The GEA 4-point scale assessed eyelash prominence from 1 (minimal) to 4 (very marked). Domain 2 of the ESQ assessed subjective attributes of confidence, attractiveness, and professionalism rated on a 5-point scale from 1 (very much disagree) to 5 (very much agree) for a total score between 3 and 15.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Upper Eyelash Length at Month 4","description":"Change from Baseline to in upper eyelash length at Month 4, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.40","spread":"1.085"},{"groupId":"OG001","value":"5.42","spread":"1.138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"1.110"},{"groupId":"OG001","value":"0.07","spread":"1.015"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Average Progressive Upper Eyelash Thickness at Month 4","description":"Change from baseline in average progressive upper eyelash thickness at Month 4 was measured within 3 preset areas. Eyelash thickness was assessed across both eyes as an average of the 3 preset areas measured in millimeters squared (mm\\^2). Changes from baseline at Month 4 represented by positive values indicated increased eyelash thickness, and changes from baseline represented by negative values indicated thinner eyelash thickness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.376"},{"groupId":"OG001","value":"0.82","spread":"0.598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"0.471"},{"groupId":"OG001","value":"-0.07","spread":"0.520"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Upper Eyelash Darkness at Month 4","description":"Change from baseline in upper eyelash darkness at Month 4 was determined by lash intensity within the spline (a narrow area approximately 5 pixels wide that bisects the area of interest). Upper eyelash darkness was measured in both eyes and averaged for analysis. Colors ranged from black=0 to white=255. Lower numbers on this continuum indicated darker colors. A negative number value change from baseline indicated increased eyelash darkening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151.36","spread":"24.670"},{"groupId":"OG001","value":"148.82","spread":"26.445"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.55","spread":"20.787"},{"groupId":"OG001","value":"-2.60","spread":"18.592"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Subjects With at Least a 1-Grade Improvement in Global Eyelash Assessment (GEA) Score at Month 4","description":"Percentage of subjects with at least a 1-grade improvement in GEA score at Month 4. The GEA scale is an investigator-graded 4-point scale of overall eyelash prominence where 1=minimal, 2=moderate, 3=marked, and 4=very marked prominence.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"28.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":214},"commonTop":["Conjunctival Hyperaemia","Punctate Keratitis","Erythema of Eyelid","Eyelids Pruritus","Upper Respiratory Tract Infection"]}}}